Hoth Therapeutics, Inc. has announced the expansion of its Phase II clinical trial for HT-001, aimed at treating skin toxicities in cancer patients using Epidermal Growth Factor Receptor Inhibitors (EGFRi), into European Union countries. The company has engaged with ICON Clinical Research Limited to manage the trial, leveraging their experience in clinical trial management. This expansion is part of Hoth's strategy to complete patient enrollment for the Phase II trial and establish a foundation for a future global Phase III trial. The trial, which is already recruiting patients in multiple sites across the United States, is a Phase 2a dose-ranging study focused on evaluating the efficacy, safety, and tolerability of the topical treatment HT-001. Additional regulatory approvals from several EU countries are anticipated in the coming months. No results from the trial have been presented yet.